Our work is focused on:
Viral vaccines prevent diseases caused by viruses. They work by inducing an immune response against the viruses in vaccinated people, imitating a natural infection without causing the illness. This helps the body’s immune system to fight off future infections by the natural, ‘wild’ viruses.
Three kinds of viral vaccines are currently licensed in Europe:
Our group studies the first type – live, attenuated vaccine viruses – in particular vaccines against rotavirus, varicella zoster virus, measles, mumps and rubella (MMR) virus infections.
We prepare, validate and provide reference materials to standardise viral assays. We also perform long-term stability studies for reference materials and we organise collaborative studies to assess new references and methods.
We independently test RotaTeq rotavirus, measles, mumps and rubella(MMR) – MMR VaxPro and Priorix – and varicella zoster vaccines for release onto the European market and for the World Health Organisation (WHO). We also perform tests to assess the integrity of anti-rubella antibody preparations.
NIBSC is an official medicines control laboratory (OMCL) and our team performs official control authority batch release (OCABR) within the European OMCL network, under ISO 17025 accreditation of the United Kingdom accreditation service (UKAS).
This involves virological and molecular tests to assess the identity, potency and thermostability of the vaccines by:
The team runs the Virology cell laboratory and provides about 20 mammalian cell lines for the control, research and standardisation work in the division. This is done according to the requirements of ISO 9001.
Vaccine manufacturers prepare live viral vaccines in specialised cell cultures which allow the viruses to be grown and produced in large quantities.
The vaccine viruses are attenuated. This means that they have been weakened by adaptation to the cell substrates, their virulent properties have been disabled and they are less dangerous than the naturally occurring viruses while still making recipients of the vaccine immune.
Producing live viral vaccines risks introducing unwanted mutations or adventitious agents during the growth of the viruses in the cells.
It is a mandatory regulatory requirement for manufacturers to test their products for contamination with unwanted viruses and for consistency of quality. We are developing next generation sequencing – NGS or deep sequencing – as a novel tool for this type of regulatory work and for research purposes.
PhD students play an important role in our team. As part of an Institute-funded PhD programme in partnership with Imperial College, we recently undertook fundamental research that helped us understand how mumps virus populations change during propagation.
Another recent PhD project studied different cell-based models for mumps virus growth. This year, we also initiated a new project examining varicella zoster vaccines.
We investigate public health issues associated with live viral vaccines. We recently carried out an investigation into the contamination of rotavirus vaccines with porcine circovirus.
We also studied whether mumps-like symptoms observed in vaccine recipients in Thailand were as a result of the mumps vaccine they had received. We collaborate with other teams across the Institute on a number of research and development projects:
Dr Silke Schepelmann, Principal scientistDr Sarah Connaughton, Post-doctoral scientist Sheela Hart, Scientist Dr Edward Mee, Post-doctoral scientistDanielle Beeson, Scientist
67/182: Anti-Rubella Serum, Human 90/534: Mumps Vaccine (Live) 91/688: Rubella Vaccine (Live) 92/648: Measles Vaccine (Live) 97/648: Anti-Measles serum (3rd International Standard) RUBI-1-94: Anti-rubella Immunoglobulin, Human